{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:46:54Z","timestamp":1794631614631,"version":"4.9.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Metformin, a widely prescribed treatment for type 2 diabetes mellitus (T2DM), demonstrates significant inter-individual variability in its therapeutic response. This variability is potentially driven by genetic differences in drug transporters. Among these transporters, the organic cation transporter 2 (OCT2) plays a critical role in the pharmacokinetics of metformin by mediating its uptake into renal epithelial cells for excretion. This review explores the potential impact of genetic variations in OCT2 gene (<jats:italic>SLC22A2<\/jats:italic>) on the pharmacokinetics and pharmacodynamics of metformin. These genetic variations can alter metformin accumulation in the kidneys, impacting its overall clearance and therapeutic effectiveness. Furthermore, the interactions of metformin with other drugs, especially in T2DM patients, can compromise its pharmacokinetics. Thus, it is important to consider the influence of genetic variability and potential drug interactions when prescribing metformin. Incorporating genetic testing into clinical decision-making could help optimize dosing strategies and improve treatment outcomes, particularly when managing patients with complex comorbid conditions. <\/jats:p>","DOI":"10.1186\/s12967-025-06720-y","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:56:00Z","timestamp":1754582160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Influence of OCT2 gene variants on metformin efficacy in type 2 diabetes: insights into pharmacogenomics and drug interactions"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-8985","authenticated-orcid":false,"given":"Ma\u2019mon M.","family":"Hatmal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abuyaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. I.","family":"Al-Hatamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Tayyem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin N.","family":"Olaimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Aolymat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Abuawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Odeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Qawaqzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"9","key":"6720_CR1","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/ijms21093240","volume":"21","author":"L Agius","year":"2020","unstructured":"Agius L, Ford BE, Chachra SS. The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective. Int J Mol Sci. 2020;21(9):3240.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6720_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4103\/1735-5362.389949","volume":"18","author":"A Ahmed","year":"2023","unstructured":"Ahmed A, Elsadek HM, Shalaby SM, Elnahas HM. Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes. Res Pharm Sci. 2023;18(6):614\u201325.","journal-title":"Res Pharm Sci"},{"issue":"2","key":"6720_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.tox.2008.06.009","volume":"250","author":"LM Aleksunes","year":"2008","unstructured":"Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology. 2008;250(2):82\u20138.","journal-title":"Toxicology"},{"issue":"48","key":"6720_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040684","volume":"103","author":"HM AlKreathy","year":"2024","unstructured":"AlKreathy HM, Alzahrani AA, Esmat A, Damanhouri ZA. Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes. Medicine (Baltimore). 2024;103(48): e40684.","journal-title":"Medicine (Baltimore)"},{"key":"6720_CR5","doi-asserted-by":"crossref","unstructured":"American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62-67.","DOI":"10.2337\/dc09-S062"},{"issue":"9","key":"6720_CR6","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/jcm8091471","volume":"8","author":"A Anguita-Ruiz","year":"2019","unstructured":"Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vazquez-Cobela R, Latorre-Millan M, Canete MD, Caballero-Villarraso J, Gil A, et al. Common variants in 22 genes regulate response to metformin intervention in children with obesity: a pharmacogenetic study of a randomized controlled trial. J Clin Med. 2019;8(9):1471.","journal-title":"J Clin Med"},{"issue":"7","key":"6720_CR7","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1172\/JCI10665","volume":"106","author":"LJ Baier","year":"2000","unstructured":"Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, Mott D, Knowler WC, Cox NJ, Horikawa Y, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest. 2000;106(7):R69-73.","journal-title":"J Clin Invest"},{"issue":"8","key":"6720_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1124\/dmd.119.086579","volume":"47","author":"A Basit","year":"2019","unstructured":"Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos. 2019;47(8):802\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"6720_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/FPC.0b013e328333bb11","volume":"20","author":"ML Becker","year":"2010","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010;20(1):38\u201344.","journal-title":"Pharmacogenet Genomics"},{"key":"6720_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lfs.2018.03.012","volume":"200","author":"JRL Benzi","year":"2018","unstructured":"Benzi JRL, Yamamoto PA, Stevens JH, Baviera AM, de Moraes NV. The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. Life Sci. 2018;200:63\u20138.","journal-title":"Life Sci"},{"issue":"3","key":"6720_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/genes14030536","volume":"14","author":"DN Binjawhar","year":"2023","unstructured":"Binjawhar DN, Ansari MGA, Sabico S, Hussain SD, Alenad AM, Alokail MS, Al-Masri AA, Al-Daghri NM. Genetic Variants of HNF4A, WFS1, DUSP9, FTO, and ZFAND6 genes are associated with prediabetes susceptibility and inflammatory markers in the saudi arabian population. Genes (Basel). 2023;14(3):536.","journal-title":"Genes (Basel)."},{"key":"6720_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101454","volume":"35","author":"GA Brooks","year":"2020","unstructured":"Brooks GA. Lactate as a fulcrum of metabolism. Redox Biol. 2020;35: 101454.","journal-title":"Redox Biol"},{"issue":"8","key":"6720_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003947","volume":"3","author":"WA Catterall","year":"2011","unstructured":"Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3(8): a003947.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6720_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fendo.2013.00037","volume":"4","author":"ME Cerf","year":"2013","unstructured":"Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"6720_CR15","first-page":"1149","volume":"14","author":"P Chan","year":"2018","unstructured":"Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. Metformin transporter pharmacogenomics: Insights into drug disposition-where are we now? Expert Opin Drug Metab Toxicol. 2018;14(11):1149\u201359.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5727","key":"6720_CR16","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1126\/science.1108595","volume":"308","author":"JP Changeux","year":"2005","unstructured":"Changeux JP, Edelstein SJ. Allosteric mechanisms of signal transduction. Science. 2005;308(5727):1424\u20138.","journal-title":"Science"},{"issue":"11","key":"6720_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FPC.0b013e32833fe789","volume":"20","author":"L Chen","year":"2010","unstructured":"Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics. 2010;20(11):687\u201399.","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"6720_CR18","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3390\/biomedicines10102546","volume":"10","author":"P Chen","year":"2022","unstructured":"Chen P, Cao Y, Chen S, Liu Z, Chen S, Guo Y. Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients. Biomedicines. 2022;10(10):2546.","journal-title":"Biomedicines"},{"issue":"7","key":"6720_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","volume":"19","author":"Y Chen","year":"2009","unstructured":"Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009;19(7):497\u2013504.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"6720_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/clpt.2010.266","volume":"89","author":"SK Cho","year":"2011","unstructured":"Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011;89(3):416\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"6720_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2133\/dmpk.23.243","volume":"23","author":"MK Choi","year":"2008","unstructured":"Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243\u201353.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"6720_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FPC.0b013e328364a57d","volume":"23","author":"MM Christensen","year":"2013","unstructured":"Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013;23(10):526\u201334.","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"6720_CR23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dci20-0022","volume":"43","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC, Hattersley AT, Hivert MF, Lee CG, McCarthy MI, Nolan JJ, Norris JM, Pearson ER, et al. Precision medicine in diabetes: a consensus report from the american diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2020;43(7):1617\u201335.","journal-title":"Diabetes Care"},{"key":"6720_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.607613","volume":"11","author":"G Ciarimboli","year":"2020","unstructured":"Ciarimboli G. Regulation mechanisms of expression and function of organic cation transporter 1. Front Pharmacol. 2020;11: 607613.","journal-title":"Front Pharmacol"},{"key":"6720_CR25","doi-asserted-by":"crossref","unstructured":"Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010;176(3):1169\u20131180.","DOI":"10.2353\/ajpath.2010.090610"},{"issue":"4","key":"6720_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/1078-0432.CCR-11-2503","volume":"18","author":"G Ciarimboli","year":"2012","unstructured":"Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RH, Yang W, et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012;18(4):1101\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6720_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.7150\/ijms.77206","volume":"20","author":"ZA Damanhouri","year":"2023","unstructured":"Damanhouri ZA, Alkreathy HM, Alharbi FA, Abualhamail H, Ahmad MS. A review of the impact of pharmacogenetics and metabolomics on the efficacy of metformin in type 2 diabetes. Int J Med Sci. 2023;20(1):142\u201350.","journal-title":"Int J Med Sci"},{"issue":"2","key":"6720_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","volume":"65","author":"R DeFronzo","year":"2016","unstructured":"DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20\u20139.","journal-title":"Metabolism"},{"key":"6720_CR29","unstructured":"World Health Organization. 2024; [accessed 21 May 2025]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"issue":"1","key":"6720_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/21556660.2019.1619571","volume":"8","author":"AIM Ebid","year":"2019","unstructured":"Ebid AIM, Ehab M, Ismail A, Soror S, Mahmoud MA. The influence of SLC22A1 rs622342 and ABCC8 rs757110 genetic variants on the efficacy of metformin and glimepiride combination therapy in Egyptian patients with type 2 diabetes. J Drug Assess. 2019;8(1):115\u201321.","journal-title":"J Drug Assess"},{"key":"6720_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.751885","volume":"12","author":"CS ElHajj","year":"2021","unstructured":"ElHajj CS, Sayed NS, Abdelsamad HS, Almahmeed W, Khandoker AH, Jelinek HF, Alsafar HS. Genetic variants and their associations to type 2 diabetes mellitus complications in the united Arab emirates. Front Endocrinol (Lausanne). 2021;12: 751885.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"6720_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.357","volume":"5","author":"R Elsby","year":"2017","unstructured":"Elsby R, Chidlaw S, Outteridge S, Pickering S, Radcliffe A, Sullivan R, Jones H, Butler P. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. Pharmacol Res Perspect. 2017;5(5): e00357.","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"6720_CR33","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-07-4793","volume":"14","author":"KK Filipski","year":"2008","unstructured":"Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14(12):3875\u201380.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6720_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460\u201376.","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"6720_CR35","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1158\/1078-0432.CCR-10-0949","volume":"16","author":"RM Franke","year":"2010","unstructured":"Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A. Influence of Oct1\/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res. 2010;16(16):4198\u2013206.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6720_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jps.20536","volume":"95","author":"T Fujita","year":"2006","unstructured":"Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci. 2006;95(1):25\u201336.","journal-title":"J Pharm Sci"},{"issue":"17","key":"6720_CR37","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martin C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275.","journal-title":"Int J Mol Sci"},{"key":"6720_CR38","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.2147\/DMSO.S390752","volume":"16","author":"R Galiero","year":"2023","unstructured":"Galiero R, Caturano A, Vetrano E, Monda M, Marfella R, Sardu C, Salvatore T, Rinaldi L, Sasso FC. Precision medicine in type 2 diabetes mellitus: utility and limitations. Diabetes Metab Syndr Obes. 2023;16:3669\u201389.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"6720_CR39","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00429-016-1315-9","volume":"222","author":"PJ Gasser","year":"2017","unstructured":"Gasser PJ, Hurley MM, Chan J, Pickel VM. Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct. 2017;222(4):1913\u201328.","journal-title":"Brain Struct Funct"},{"issue":"5","key":"6720_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41583-021-00444-w","volume":"22","author":"G Goodwin","year":"2021","unstructured":"Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021;22(5):263\u201374.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"6720_CR41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/clpt.2014.109","volume":"96","author":"S Goswami","year":"2014","unstructured":"Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2014;96(3):370\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"6720_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"47","key":"6720_CR43","doi-asserted-by":"publisher","first-page":"30915","DOI":"10.1074\/jbc.273.47.30915","volume":"273","author":"D Grundemann","year":"1998","unstructured":"Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998;273(47):30915\u201320.","journal-title":"J Biol Chem"},{"issue":"9","key":"6720_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136451","volume":"10","author":"K Hacker","year":"2015","unstructured":"Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O. Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates. PLoS ONE. 2015;10(9): e0136451.","journal-title":"PLoS ONE"},{"issue":"6","key":"6720_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/tpj.2013.33","volume":"13","author":"SB Haga","year":"2013","unstructured":"Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J. 2013;13(6):481\u20133.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"6720_CR46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/pharmaceutics12050468","volume":"12","author":"SY Han","year":"2020","unstructured":"Han SY, Choi YH. Pharmacokinetic interaction between metformin and verapamil in rats: inhibition of the OCT2-mediated renal excretion of metformin by verapamil. Pharmaceutics. 2020;12(5):468.","journal-title":"Pharmaceutics"},{"issue":"1","key":"6720_CR47","first-page":"544","volume":"57","author":"T Hansen","year":"2002","unstructured":"Hansen T. Type 2 diabetes mellitus\u2014a multifactorial disease. Ann Univ Mariae Curie Sklodowska Med. 2002;57(1):544\u20139.","journal-title":"Ann Univ Mariae Curie Sklodowska Med"},{"issue":"5","key":"6720_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00424-003-1192-y","volume":"447","author":"MA Hediger","year":"2004","unstructured":"Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 2004;447(5):465\u20138.","journal-title":"Pflugers Arch"},{"issue":"3","key":"6720_CR49","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/ijms23031264","volume":"23","author":"R Herman","year":"2022","unstructured":"Herman R, Kravos NA, Jensterle M, Janez A, Dolzan V. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci. 2022;23(3):1264.","journal-title":"Int J Mol Sci"},{"key":"6720_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-60327-411-1_2","volume":"578","author":"R Hunt","year":"2009","unstructured":"Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C. Silent (synonymous) SNPs: Should we care about them? Methods Mol Biol. 2009;578:23\u201339.","journal-title":"Methods Mol Biol"},{"key":"6720_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.928016","volume":"13","author":"Y Jia","year":"2022","unstructured":"Jia Y, Liu Y, Feng L, Sun S, Sun G. Role of glucagon and its receptor in the pathogenesis of diabetes. Front Endocrinol (Lausanne). 2022;13: 928016.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6720_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13293-015-0020-3","volume":"6","author":"S Joseph","year":"2015","unstructured":"Joseph S, Nicolson TJ, Hammons G, Word B, Green-Knox B, Lyn-Cook B. Expression of drug transporters in human kidney: impact of sex, age, and ethnicity. Biol Sex Differ. 2015;6:4.","journal-title":"Biol Sex Differ"},{"issue":"4","key":"6720_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1124\/dmd.106.013581","volume":"35","author":"HJ Kang","year":"2007","unstructured":"Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, Zhou HH, Lee SS, Shin JG. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos. 2007;35(4):667\u201375.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"6720_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.diabres.2015.01.024","volume":"108","author":"Z Kashi","year":"2015","unstructured":"Kashi Z, Masoumi P, Mahrooz A, Hashemi-Soteh MB, Bahar A, Alizadeh A. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. Diabetes Res Clin Pract. 2015;108(1):78\u201383.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"6720_CR55","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.1038\/s41467-022-34284-8","volume":"13","author":"B Khanppnavar","year":"2022","unstructured":"Khanppnavar B, Maier J, Herborg F, Gradisch R, Lazzarin E, Luethi D, Yang JW, Qi C, Holy M, Jantsch K, et al. Structural basis of organic cation transporter-3 inhibition. Nat Commun. 2022;13(1):6714.","journal-title":"Nat Commun"},{"key":"6720_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.bioeng.9.060906.152037","volume":"9","author":"S Kim","year":"2007","unstructured":"Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng. 2007;9:289\u2013320.","journal-title":"Annu Rev Biomed Eng"},{"issue":"5","key":"6720_CR57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2133\/dmpk.20.379","volume":"20","author":"N Kimura","year":"2005","unstructured":"Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20(5):379\u201386.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"6720_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11095-004-1193-3","volume":"22","author":"N Kimura","year":"2005","unstructured":"Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22(2):255\u20139.","journal-title":"Pharm Res"},{"issue":"7","key":"6720_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tips.2004.05.005","volume":"25","author":"H Koepsell","year":"2004","unstructured":"Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci. 2004;25(7):375\u201381.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"6720_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/sj.bjp.0704878","volume":"137","author":"N Kumar","year":"2002","unstructured":"Kumar N, Dey CS. Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. Br J Pharmacol. 2002;137(3):329\u201336.","journal-title":"Br J Pharmacol"},{"key":"6720_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106182","volume":"181","author":"M Kumawat","year":"2023","unstructured":"Kumawat M, Nabi B, Daswani M, Viquar I, Pal N, Sharma P, Tiwari S, Sarma DK, Shubham S, Kumar M. Role of bacterial efflux pump proteins in antibiotic resistance across microbial species. Microb Pathog. 2023;181: 106182.","journal-title":"Microb Pathog"},{"issue":"3","key":"6720_CR62","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/gim.2016.103","volume":"19","author":"K Lall","year":"2017","unstructured":"Lall K, Magi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19(3):322\u20139.","journal-title":"Genet Med"},{"issue":"1","key":"6720_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77\u201396.","journal-title":"Endocr Rev"},{"issue":"4","key":"6720_CR64","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2217\/pgs.14.182","volume":"16","author":"C Lanvers-Kaminsky","year":"2015","unstructured":"Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jurgens H, Am Zehnhoff-Dinnesen AG, et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015;16(4):323\u201332.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"6720_CR65","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00008571-200207000-00007","volume":"12","author":"MK Leabman","year":"2002","unstructured":"Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12(5):395\u2013405.","journal-title":"Pharmacogenetics"},{"key":"6720_CR66","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.2147\/OTT.S212088","volume":"12","author":"J Li","year":"2019","unstructured":"Li J, Yang Z, Tuo B. Role of OCT1 in hepatocellular carcinoma. Onco Targets Ther. 2019;12:6013\u201322.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"6720_CR67","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/aps.2009.189","volume":"31","author":"Q Li","year":"2010","unstructured":"Li Q, Liu F, Zheng TS, Tang JL, Lu HJ, Jia WP. SLC22A2 gene 808 G\/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin. 2010;31(2):184\u201390.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"6720_CR68","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/17512433.2022.2118714","volume":"15","author":"S Li","year":"2022","unstructured":"Li S, Xu B, Fan S, Kang B, Deng L, Chen D, Yang B, Tang F, He Z, Xue Y, Zhou JC. Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin. Expert Rev Clin Pharmacol. 2022;15(9):1107\u201317.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"6720_CR69","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","volume":"106","author":"X Liang","year":"2017","unstructured":"Liang X, Giacomini KM. Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci. 2017;106(9):2245\u201350.","journal-title":"J Pharm Sci"},{"issue":"8","key":"6720_CR70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"6720_CR71","first-page":"397","volume":"10","author":"L Love-Gregory","year":"2007","unstructured":"Love-Gregory L, Permutt MA. HNF4A genetic variants: role in diabetes. Curr Opin Clin Nutr Metab Care. 2007;10(4):397\u2013402.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"6720_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jpm8020014","volume":"8","author":"E Lozano","year":"2018","unstructured":"Lozano E, Briz O, Macias RIR, Serrano MA, Marin JJG, Herraez E. Genetic heterogeneity of SLC22 family of transporters in drug disposition. J Pers Med. 2018;8(2):14.","journal-title":"J Pers Med"},{"key":"6720_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/692071","volume":"2013","author":"E Lozano","year":"2013","unstructured":"Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A, Marin JJ. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int. 2013;2013: 692071.","journal-title":"Biomed Res Int"},{"issue":"5","key":"6720_CR74","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13318-015-0278-1","volume":"41","author":"YR Ma","year":"2016","unstructured":"Ma YR, Qin HY, Jin YW, Huang J, Han M, Wang XD, Zhang GQ, Zhou Y, Rao Z, Wu XA. Gender-related differences in the expression of organic cation transporter 2 and its role in urinary excretion of metformin in rats. Eur J Drug Metab Pharmacokinet. 2016;41(5):559\u201365.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6720_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jff.2019.05.021","volume":"59","author":"EPM Mato","year":"2019","unstructured":"Mato EPM, Essop MF, Owira PMO. Effects of naringenin on renal expression of organic cation transporter 1 and 2 proteins and metformin disposition in diabetic rats. J Funct Foods. 2019;59:1\u20137.","journal-title":"J Funct Foods"},{"issue":"3","key":"6720_CR76","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335.","journal-title":"Diabetologia"},{"key":"6720_CR77","doi-asserted-by":"crossref","unstructured":"Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1\/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298(4):F997\u2013F1005.","DOI":"10.1152\/ajprenal.00431.2009"},{"issue":"1","key":"6720_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/dmd.109.028142","volume":"38","author":"T Minematsu","year":"2010","unstructured":"Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H. Characterization of human organic cation transporter 1 (OCT1\/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010;38(1):1\u20134.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"6720_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0011-5029(89)90021-7","volume":"35","author":"BA Mizock","year":"1989","unstructured":"Mizock BA. Lactic acidosis. Dis Mon. 1989;35(4):233\u2013300.","journal-title":"Dis Mon"},{"issue":"28","key":"6720_CR80","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1523\/JNEUROSCI.1544-10.2010","volume":"30","author":"SS More","year":"2010","unstructured":"More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010;30(28):9500\u20139.","journal-title":"J Neurosci"},{"issue":"2","key":"6720_CR81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/dmd.119.088781","volume":"48","author":"BL Morse","year":"2020","unstructured":"Morse BL, Kolur A, Hudson LR, Hogan AT, Chen LH, Brackman RM, Sawada GA, Fallon JK, Smith PC, Hillgren KM. Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1\/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake. Drug Metab Dispos. 2020;48(2):93\u2013105.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"6720_CR82","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1208\/s12248-013-9465-7","volume":"15","author":"H Motohashi","year":"2013","unstructured":"Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013;15(2):581\u20138.","journal-title":"AAPS J"},{"issue":"8","key":"6720_CR83","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1021\/acs.molpharmaceut.8b00416","volume":"15","author":"F Muller","year":"2018","unstructured":"Muller F, Weitz D, Mertsch K, Konig J, Fromm MF. Importance of OCT2 and MATE1 for the cimetidine-metformin interaction: insights from investigations of polarized transport in single- and double-transfected MDCK cells with a focus on perpetrator disposition. Mol Pharm. 2018;15(8):3425\u201333.","journal-title":"Mol Pharm"},{"issue":"3","key":"6720_CR84","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3803\/EnM.2018.33.3.364","volume":"33","author":"JS Nam","year":"2018","unstructured":"Nam JS, Han JW, Lee SB, You JH, Kim MJ, Kang S, Park JS, Ahn CW. Calpain-10 and adiponectin gene polymorphisms in Korean type 2 diabetes patients. Endocrinol Metab (Seoul). 2018;33(3):364\u201371.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"6720_CR85","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/genes13081310","volume":"13","author":"YA Nasykhova","year":"2022","unstructured":"Nasykhova YA, Barbitoff YA, Tonyan ZN, Danilova MM, Nevzorov IA, Komandresova TM, Mikhailova AA, Vasilieva TV, Glavnova OB, Yarmolinskaya MI, et al. Genetic and phenotypic factors affecting glycemic response to metformin therapy in patients with type 2 diabetes mellitus. Genes (Basel). 2022;13(8):1310.","journal-title":"Genes (Basel)"},{"issue":"18","key":"6720_CR86","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.3390\/ijms21186842","volume":"21","author":"YA Nasykhova","year":"2020","unstructured":"Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes-progress and prospects. Int J Mol Sci. 2020;21(18):6842.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"6720_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022163","volume":"6","author":"AT Nies","year":"2011","unstructured":"Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE. 2011;6(7): e22163.","journal-title":"PLoS ONE"},{"issue":"4","key":"6720_CR88","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5001\/omj.2012.68","volume":"27","author":"AB Olokoba","year":"2012","unstructured":"Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269\u201373.","journal-title":"Oman Med J"},{"key":"6720_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/967826","volume":"2014","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014: 967826.","journal-title":"Biomed Res Int"},{"issue":"9","key":"6720_CR90","doi-asserted-by":"publisher","first-page":"8742","DOI":"10.18632\/aging.103095","volume":"12","author":"Q Pan","year":"2020","unstructured":"Pan Q, Lu X, Zhao C, Liao S, Chen X, Guo F, Yang C, Liu HF. Metformin: the updated protective property in kidney disease. Aging (Albany NY). 2020;12(9):8742\u201359.","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"6720_CR91","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.2337\/db13-1367","volume":"63","author":"AC Pawlyk","year":"2014","unstructured":"Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63(8):2590\u20139.","journal-title":"Diabetes"},{"key":"6720_CR92","doi-asserted-by":"publisher","first-page":"1183879","DOI":"10.3389\/fpubh.2023.1183879","volume":"11","author":"A Peng","year":"2023","unstructured":"Peng A, Gong C, Xu Y, Liang X, Chen X, Hong W, Yan J. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis. Front Public Health. 2023;11:1183879.","journal-title":"Front Public Health"},{"key":"6720_CR93","doi-asserted-by":"crossref","unstructured":"Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int. 2014;111(5):69\u201381; quiz 82.","DOI":"10.3238\/arztebl.2014.0069"},{"issue":"4","key":"6720_CR94","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/ALN.0000000000003655","volume":"134","author":"RM Pino","year":"2021","unstructured":"Pino RM, Singh J. Appropriate clinical use of lactate measurements. Anesthesiology. 2021;134(4):637\u201344.","journal-title":"Anesthesiology"},{"issue":"1","key":"6720_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000816","volume":"8","author":"RA Posma","year":"2020","unstructured":"Posma RA, Venema LH, Huijink TM, Westerkamp AC, Wessels AMA, De Vries NJ, Doesburg F, Roggeveld J, Ottens PJ, Touw DJ, et al. Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. BMJ Open Diabetes Res Care. 2020;8(1): e000816.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"6720_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/genes6010087","volume":"6","author":"RB Prasad","year":"2015","unstructured":"Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel). 2015;6(1):87\u2013123.","journal-title":"Genes (Basel)"},{"issue":"5","key":"6720_CR97","volume":"11","author":"V Rajasurya","year":"2019","unstructured":"Rajasurya V, Anjum H, Surani S. Metformin use and metformin-associated lactic acidosis in intensive care unit patients with diabetes. Cureus. 2019;11(5): e4739.","journal-title":"Cureus"},{"key":"6720_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.839437","volume":"13","author":"R Rao","year":"2022","unstructured":"Rao R, Shah S, Bhattacharya D, Toukam DK, Caceres R, Pomeranz Krummel DA, Sengupta S. Ligand-gated ion channels as targets for treatment and management of cancers. Front Physiol. 2022;13: 839437.","journal-title":"Front Physiol"},{"issue":"3","key":"6720_CR99","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13318-014-0214-9","volume":"40","author":"J Ren","year":"2015","unstructured":"Ren J, Zhou Y, Zhang G, Zhou L, Zhao J, Wei Y, Wu X. Role of age-related decrease of renal organic cation transporter 2 in the effect of atenolol on renal excretion of metformin in rats. Eur J Drug Metab Pharmacokinet. 2015;40(3):349\u201354.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"6720_CR100","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385.","journal-title":"Diabetologia"},{"issue":"5","key":"6720_CR101","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165(5):1260\u201387.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"6720_CR102","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2337\/db17-1164","volume":"67","author":"DM Rotroff","year":"2018","unstructured":"Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, et al. Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes. 2018;67(7):1428\u201340.","journal-title":"Diabetes"},{"issue":"2","key":"6720_CR103","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jgeb.2018.01.003","volume":"16","author":"AA Sajib","year":"2018","unstructured":"Sajib AA, Islam T, Paul N, Yeasmin S. Interaction of rs316019 variants of SLC22A2 with metformin and other drugs- an in silico analysis. J Genet Eng Biotechnol. 2018;16(2):769\u201375.","journal-title":"J Genet Eng Biotechnol"},{"issue":"9","key":"6720_CR104","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586\u201393.","journal-title":"Diabetologia"},{"issue":"2","key":"6720_CR105","doi-asserted-by":"publisher","first-page":"R44","DOI":"10.1016\/j.cub.2004.12.050","volume":"15","author":"Z Sands","year":"2005","unstructured":"Sands Z, Grottesi A, Sansom MS. Voltage-gated ion channels. Curr Biol. 2005;15(2):R44-47.","journal-title":"Curr Biol"},{"key":"6720_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.688885","volume":"9","author":"S Schorn","year":"2021","unstructured":"Schorn S, Dicke AK, Neugebauer U, Schroter R, Friedrich M, Reuter S, Ciarimboli G. Expression and function of organic cation transporter 2 in pancreas. Front Cell Dev Biol. 2021;9: 688885.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"6720_CR107","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10038-006-0087-0","volume":"52","author":"E Shikata","year":"2007","unstructured":"Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52(2):117\u201322.","journal-title":"J Hum Genet"},{"issue":"9","key":"6720_CR108","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","volume":"26","author":"S Shugarts","year":"2009","unstructured":"Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9):2039\u201354.","journal-title":"Pharm Res"},{"issue":"5","key":"6720_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036637","volume":"7","author":"IS Song","year":"2012","unstructured":"Song IS, Lee DY, Shin MH, Kim H, Ahn YG, Park I, Kim KH, Kind T, Shin JG, Fiehn O, Liu KH. Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS ONE. 2012;7(5): e36637.","journal-title":"PLoS ONE"},{"issue":"5","key":"6720_CR110","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/clpt.2008.61","volume":"84","author":"IS Song","year":"2008","unstructured":"Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84(5):559\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"6720_CR111","volume":"15","author":"F Sugandh","year":"2023","unstructured":"Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, Memon UA, Bai K, Kashif M, Varrassi G, et al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023;15(8): e43697.","journal-title":"Cureus"},{"key":"6720_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"6720_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669814","volume":"12","author":"J Tan","year":"2021","unstructured":"Tan J, Wang Y, Liu S, Shi Q, Zhou X, Zhou Y, Yang X, Chen P, Li S. Long-acting metformin Vs. metformin immediate release in patients with type 2 diabetes: a systematic review. Front Pharmacol. 2021;12: 669814.","journal-title":"Front Pharmacol"},{"issue":"4","key":"6720_CR114","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2337\/db12-0073","volume":"61","author":"R Taylor","year":"2012","unstructured":"Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012;61(4):778\u20139.","journal-title":"Diabetes"},{"issue":"12","key":"6720_CR115","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1128\/AAC.01471-16","volume":"60","author":"LH Te Brake","year":"2016","unstructured":"Te Brake LH, van den Heuvel JJ, Buaben AO, van Crevel R, Bilos A, Russel FG, Aarnoutse RE, Koenderink JB. Moxifloxacin is a potent in vitro inhibitor of OCT- and MATE-mediated transport of metformin and ethambutol. Antimicrob Agents Chemother. 2016;60(12):7105\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6720_CR116","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/dmrr.578","volume":"21","author":"MD Turner","year":"2005","unstructured":"Turner MD, Cassell PG, Hitman GA. Calpain-10: from genome search to function. Diabetes Metab Res Rev. 2005;21(6):505\u201314.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"6720_CR117","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2009.92","volume":"86","author":"MV Tzvetkov","year":"2009","unstructured":"Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299\u2013306.","journal-title":"Clin Pharmacol Ther"},{"key":"6720_CR118","doi-asserted-by":"crossref","unstructured":"Van Ness KP, Kelly EJ. Excretory processes in toxicology: drug transporters in drug development. In: McQueen CA, editor. Comprehensive Toxicology. Elsevier Science. 2018.","DOI":"10.1016\/B978-0-12-801238-3.64206-X"},{"issue":"9","key":"6720_CR119","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/jmg.38.9.569","volume":"38","author":"J van Tilburg","year":"2001","unstructured":"van Tilburg J, van Haeften TW, Pearson P, Wijmenga C. Defining the genetic contribution of type 2 diabetes mellitus. J Med Genet. 2001;38(9):569\u201378.","journal-title":"J Med Genet"},{"issue":"3","key":"6720_CR120","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3(3):281\u201390.","journal-title":"Hum Genomics"},{"issue":"11","key":"6720_CR121","first-page":"1008","volume":"61","author":"M Wakui","year":"2013","unstructured":"Wakui M. Analysis of single nucleotide polymorphisms (SNPs). Rinsho Byori. 2013;61(11):1008\u201317.","journal-title":"Rinsho Byori"},{"issue":"4","key":"6720_CR122","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1124\/mol.63.4.844","volume":"63","author":"DS Wang","year":"2003","unstructured":"Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 2003;63(4):844\u20138.","journal-title":"Mol Pharmacol"},{"issue":"7","key":"6720_CR123","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","volume":"18","author":"ZJ Wang","year":"2008","unstructured":"Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637\u201345.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"6720_CR124","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"DR Whiting","year":"2011","unstructured":"Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311\u201321.","journal-title":"Diabetes Res Clin Pract"},{"key":"6720_CR125","doi-asserted-by":"crossref","unstructured":"Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58(Suppl 1):31\u201339; discussion 75\u201382.","DOI":"10.2165\/00003495-199958001-00009"},{"issue":"2","key":"6720_CR126","first-page":"19","volume":"26","author":"G Wilcox","year":"2005","unstructured":"Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19\u201339.","journal-title":"Clin Biochem Rev"},{"issue":"3","key":"6720_CR127","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/omi.2016.0165","volume":"21","author":"NC Wilson","year":"2017","unstructured":"Wilson NC, Choudhury A, Carstens N, Mavri-Damelin D. Organic cation transporter 2 (OCT2\/SLC22A2) gene variation in the South African bantu-speaking population and functional promoter variants. OMICS. 2017;21(3):169\u201376.","journal-title":"OMICS"},{"issue":"6","key":"6720_CR128","doi-asserted-by":"publisher","first-page":"F1669","DOI":"10.1152\/ajprenal.00422.2019","volume":"317","author":"SH Wright","year":"2019","unstructured":"Wright SH. Molecular and cellular physiology of organic cation transporter 2. Am J Physiol Renal Physiol. 2019;317(6):F1669\u201379.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"49","key":"6720_CR129","doi-asserted-by":"publisher","first-page":"32776","DOI":"10.1074\/jbc.273.49.32776","volume":"273","author":"X Wu","year":"1998","unstructured":"Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273(49):32776\u201386.","journal-title":"J Biol Chem"},{"issue":"11","key":"6720_CR130","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.7150\/ijms.10001","volume":"11","author":"Y Wu","year":"2014","unstructured":"Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11(11):1185\u2013200.","journal-title":"Int J Med Sci"},{"issue":"1","key":"6720_CR131","first-page":"1","volume":"42","author":"Y Wu","year":"2022","unstructured":"Wu Y, Hu YL, Liu W, Sun BJ, Zhang CF, Wu LL, Liu TH. Meta-analysis Flavonoids from traditional Chinese herbs for diabetes in rats: a network Meta-analysi. J Tradit Chin Med. 2022;42(1):1\u20138.","journal-title":"J Tradit Chin Med"},{"key":"6720_CR132","first-page":"745","volume":"14","author":"D Xiao","year":"2021","unstructured":"Xiao D, Liu JY, Zhang SM, Liu RR, Yin JY, Han XY, Li X, Zhang W, Chen XP, Zhou HH, et al. A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients. Pharmgenomics Pers Med. 2021;14:745\u201355.","journal-title":"Pharmgenomics Pers Med"},{"issue":"5","key":"6720_CR133","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/pharmaceutics13050698","volume":"13","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhang Z, Li P, Kong W, Liu X, Liu L. A whole-body physiologically based pharmacokinetic model characterizing interplay of OCTs and MATEs in intestine, liver and kidney to predict drug-drug interactions of metformin with perpetrators. Pharmaceutics. 2021;13(5):698.","journal-title":"Pharmaceutics"},{"issue":"6","key":"6720_CR134","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-16-0347","volume":"175","author":"L Zaharenko","year":"2016","unstructured":"Zaharenko L, Kalnina I, Geldnere K, Konrade I, Grinberga S, Zidzik J, Javorsky M, Lejnieks A, Nikitina-Zake L, Fridmanis D, et al. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. Eur J Endocrinol. 2016;175(6):531\u201340.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"6720_CR135","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/14622416.9.5.597","volume":"9","author":"ZM Zair","year":"2008","unstructured":"Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21\/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics. 2008;9(5):597\u2013624.","journal-title":"Pharmacogenomics"},{"issue":"18","key":"6720_CR136","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.3390\/ijms21186627","volume":"21","author":"Z Zazuli","year":"2020","unstructured":"Zazuli Z, Duin N, Jansen K, Vijverberg SJH, Maitland-van der Zee AH, Masereeuw R. The impact of genetic polymorphisms in organic cation transporters on renal drug disposition. Int J Mol Sci. 2020;21(18):6627.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6720_CR137","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s13300-020-00922-x","volume":"11","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Huang SY, Sun T. Pharmacogenomic studies of current antidiabetic agents and potential new drug targets for precision medicine of diabetes. Diabetes Ther. 2020;11(11):2521\u201338.","journal-title":"Diabetes Ther"},{"issue":"7","key":"6720_CR138","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.fct.2012.03.077","volume":"50","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808 G\/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012;50(7):2289\u201393.","journal-title":"Food Chem Toxicol"},{"issue":"41","key":"6720_CR139","doi-asserted-by":"publisher","first-page":"34813","DOI":"10.1074\/jbc.M506342200","volume":"280","author":"X Zhang","year":"2005","unstructured":"Zhang X, Shirahatti NV, Mahadevan D, Wright SH. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J Biol Chem. 2005;280(41):34813\u201322.","journal-title":"J Biol Chem"},{"issue":"6","key":"6720_CR140","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.2337\/db08-0896","volume":"58","author":"K Zhou","year":"2009","unstructured":"Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434\u20139.","journal-title":"Diabetes"},{"issue":"2","key":"6720_CR141","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/07853890.2010.549144","volume":"44","author":"O Zolk","year":"2012","unstructured":"Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann Med. 2012;44(2):119\u201329.","journal-title":"Ann Med"},{"issue":"6","key":"6720_CR142","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1124\/dmd.108.023762","volume":"37","author":"O Zolk","year":"2009","unstructured":"Zolk O, Solbach TF, Konig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009;37(6):1312\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"6720_CR143","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00210-008-0369-5","volume":"379","author":"O Zolk","year":"2009","unstructured":"Zolk O, Solbach TF, Konig J, Fromm MF. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol. 2009;379(4):337\u201348.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"6720_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746208","volume":"12","author":"W Zou","year":"2021","unstructured":"Zou W, Shi B, Zeng T, Zhang Y, Huang B, Ouyang B, Cai Z, Liu M. Drug transporters in the kidney: perspectives on species differences, disease status, and molecular docking. Front Pharmacol. 2021;12: 746208.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06720-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:46:18Z","timestamp":1757346378000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6720"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06720-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"884"}}